Browse by category

Epicyt Pharma has announced positive topline results from its Phase 1/2a first-in-human study of BAFA, a first‑in‑class oral drug candidate combining a bile acid and a short‑chain fatty acid to enhance intestinal calcium uptake, in patients following Roux-en-Y gastric bypass (RYGB) surgery. The study demonstrated a statistically significant reduction in urinary calcium excretion together with improvements in key biomarkers of calcium homeostasis. Based on these encouraging fi